Germline genetics of active surveillance for prostate cancer.

Germline genetics of active surveillance for prostate cancer. - Genomics in active surveillance for prostate cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43566

Enrollment

150

Registered

2016-05-19

Start date

2016-04-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer prostate carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Signed informed consent for the PRIAS study. - Men 60 to 80 years of age.

Exclusion criteria

Exclusion criteria: - Patients with a Gleason score out of the *3+3 range. - Patients with more than 3 cores involved with cancer. - Withdrawn informed consent from the PRIAS study.;Patients that do not want to be informed about any potential life threatening abnormalities found in their DNA, cannot participate in the study.

Design outcomes

Primary

Measure	Time frame
To test SNPs that are related to the diagnosis and prognosis of aggressive prostate cancer. Relevant SNPs as detected by the Prostate SPORE Working Group and the International Consortium for Prostate Cancer Genetics will be tested.	—

Secondary

Measure	Time frame
Assess the possibilities to enhance existing risk stratification tools with genomic based information to improve patient selection for an active surveillance management strategy.	—

Countries

Netherlands

Outcome results